Table 1 The comparison of results and adverse events among pan-HDAC inhibitors in clinical trials for cancer
NCT numbers | Agent | Other agents | Inclusion | Phase | Enrollment | mPFS (months) | AEs |
|---|---|---|---|---|---|---|---|
NCT00985946 | Panobinostat | – | Neuroendocrine tumors | II | 15 | 9.9 | Fatigue (27%) |
Thrombocytopenia (20%) | |||||||
Diarrhea (13%) | |||||||
Nausea (13%) | |||||||
NCT01451268 | Panobinostat | – | Myelodysplastic syndrome | I/II | 62 | – | Thrombocytopenia (24%) |
Acute myeloid leukemia | Neutropenia (19%) | ||||||
NCT00918489 | Vorinostat | – | Soft tissue sarcoma | II | 40 | 3.2 | Hematological toxicity (15%) |
Gastrointestinal disorders (13%) | |||||||
Fatigue (10%) | |||||||
NCT01087554 | Vorinostat | Sirolimus | Advanced cancer | I | 249 | 2.1 | Thrombocytopenia (31%) |
Everolimus | Neutropenia (8%) | ||||||
Temsirolimus | Â | ||||||
NCT02944812 | Chidamide | – | Peripheral T cell lymphoma | II | 12 | - | - |
NCT02576496 | EDO-S101 | – | Hematological malignancies | I | 84 | - | - |
Multiple myeloma | |||||||
Hodgkin’s lymphoma | |||||||
Peripheral T cell lymphoma | |||||||
Non-Hodgkin’s lymphoma |